Cingulate (CING) Stock Forecast & Price Target

Cingulate is supported by a compelling risk-reward setup, as the FDA’s June 2, 2026 CRL for CTx-1301 cited only CMC issues and not clinical safety or efficacy concerns, leaving the core efficacy story intact. The company also reported $28.4M in cash in 2Q26, a net loss of $5.9M, and runway into mid-2027, which should help fund resubmission efforts while the Prasco agreement and IP protection through 2042 strengthen the commercialization case. With ADHD representing a multibillion-dollar market that reached about $18 billion in U.S. sales in 2020 and CTx-1301/CTx-1302 targeting broad patient segments, the long-term upside remains substantial if remediation and resubmission proceed successfully.

Cingulate is burdened by a highly uncertain regulatory path, as the FDA CRL appears to hinge on both CMC remediation and satisfactory facility remediation, while Bend Bioscience’s execution remains the key variable and a second FDA inspection could push CTx-1301 beyond the currently projected 3Q27 launch. The company also has no revenue, no guidance, and remains unprofitable, posting a $5.9 million net loss in Q2 2026 and a $9.3 million net loss in Q1 2026, underscoring continued cash burn without commercial offset. With clinical, reimbursement, partnership, and dilution risks still elevated, the stock’s fundamentals look fragile and dependent on several events that may not resolve favorably.